Collaboration Details

Title of Collaborative Activity:

FDA Risk Evaluations and Midigation workshop (FDA REMS)

Description of Collaborative Activity:

Participated as panelist in the Risk Evaluation and Mitigation Strategy (REMS) workshop in December. REMS is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. This workshop was on opioids and pain.

Type of Collaborative Activity:

Meeting/ Workshop

Year the Collaborative Activity Originated:

2020

NIH Participating Institutes/Centers/Office of the Director:

OD/DPCPSI/ORWH

HHS Agency Collaborators on this Activity:

FDA